| Active Not Recruiting | Treatment Duration of IPA NCT06583512 | Peking University People's Hospital | — |
| Unknown | Assessment of Volatile Organic Compounds (VOC) for the Diagnosis of Invasive Aspergillosis (IA) in Lung Transp NCT06344117 | Owlstone Ltd | — |
| Unknown | ManagemEnt of Antifungal Drug in Invasive Aspergillosis：a Real-word Study NCT06028451 | Southeast University, China | — |
| Completed | A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus NCT05707832 | CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 3 |
| Recruiting | Role of Antifungal Prophylaxis in Elderly Patients With Acute Myeloid Leukemia During Consolidation Therapy NCT06382922 | University of Rome Tor Vergata | — |
| Active Not Recruiting | Olorofim Aspergillus Infection Study NCT05101187 | F2G Biotech GmbH | Phase 3 |
| Completed | European Study of Cerebral Aspergillosis Treated With Isavuconazole NCT04486885 | Imagine Institute | — |
| Terminated | Azole-echinocandin Combination Therapy for Invasive Aspergillosis NCT04876716 | Erasmus Medical Center | Phase 3 |
| Completed | A Study to Understand How the Use of Paxlovid Affected the Healthcare Use in People With Pre-existing Conditio NCT04550936 | Pfizer | — |
| Completed | Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104) NCT04218851 | Merck Sharp & Dohme LLC | Phase 2 |
| Unknown | Amphotericin B Cholesteryl Sulfate Complex for Injection(ABCD) in the Treatment of Invasive Candidiasis and In NCT04225195 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 2 |
| Completed | A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucor NCT03816176 | Astellas Pharma Global Development, Inc. | Phase 2 |
| Recruiting | Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants NCT03717623 | Melbourne Health | Phase 4 |
| Withdrawn | Radiolabelled IV and Oral Metabolism Study of F901318 NCT02912026 | F2G Biotech GmbH | Phase 1 |
| Terminated | VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults NCT03327727 | Vical | Phase 2 |
| Completed | Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects NCT03340597 | F2G Biotech GmbH | Phase 1 |
| Recruiting | Detection of Azole Resistance Inducing Mutations on DNA Extracted Directly From Serum or Plasma of Immunocompr NCT06069505 | Bart Rijnders | — |
| Withdrawn | Drug/Drug Interactions With F901318 NCT03095547 | F2G Biotech GmbH | Phase 1 |
| Withdrawn | Pharmacokinetics of IV Formulation NCT03076905 | F2G Biotech GmbH | Phase 1 |
| Completed | Clinical Implications of Azole-Resistant Aspergillosis in Hematological Malignancy NCT03221075 | University Hospital of Cologne | — |
| Completed | Evaluation of Immediate Release Tablet NCT02808741 | F2G Biotech GmbH | Phase 1 |
| Completed | Multiple Ascending Oral Dose Study of F901318 in Healthy Subjects NCT02737371 | F2G Biotech GmbH | Phase 1 |
| Completed | Study of Potential for Interaction of Fluconazole With F901318 NCT02730442 | F2G Biotech GmbH | Phase 1 |
| Unknown | Impact of Pre-existing Invasive Aspergillosis on Allogeneic Stem Cell Transplantation NCT03014934 | European Society for Blood and Marrow Transplantation | — |
| Completed | Evaluation of the Potential for Cytochrome P450 3A4 Inhibition by F901318 Using Oral Midazolam as a Probe NCT02680808 | F2G Biotech GmbH | Phase 1 |
| Completed | Single Ascending Oral Dose Study of F901318 NCT02394483 | F2G Biotech GmbH | Phase 1 |
| Terminated | Concentrations of Voriconazole in Blood and BAL-fluid After Inhalation and Oral Administration NCT02396225 | University of Aarhus | N/A |
| Completed | F901318 Multiple Ascending Dose Study NCT02342574 | F2G Biotech GmbH | Phase 1 |
| Completed | Influence of a Combined Pharmacogenetic Score on Through Plasma Voriconazole Concentrations in Haematological NCT03067350 | University Hospital, Grenoble | — |
| Completed | F901318 Single Ascending Dose Study in Healthy Male Volunteers NCT02142153 | F2G Biotech GmbH | Phase 1 |
| Unknown | Diagnostic Accuracy of Pleural Effusion Aspergillosis Biomarker Testing NCT02104479 | Heidelberg University | — |
| Terminated | Post Marketing Study to Evaluate the Efficacy and Safety of Micafungin Treatment on Invasive Aspergillosis NCT02646774 | Astellas Pharma China, Inc. | Phase 4 |
| Unknown | An Evaluation of Sequential Computed Tomography of the Chest in Management of Invasive Pulmonal Aspergillosis NCT02773342 | University Hospital of Cologne | — |
| Completed | Exhaled Breath Analysis in the Early Detection of Aspergillosis NCT02106117 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | — |
| Recruiting | Natural History of Individuals With Immune System Problems That Lead to Fungal Infections NCT01386437 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Unknown | Diagnostic Study of Biomarkers in BAL of ICU Patients With Lung Infiltrates NCT01695499 | Heidelberg University | — |
| Unknown | Diagnostic Study of Combined Biomnarker Testing in Bronchoalveolar Lavage Samples of Immunocompromised Patient NCT01695512 | Heidelberg University | — |
| Unknown | Correlation Between Circulating Galactomannan and Beta-D-glucan and Clinical Outcome of Invasive Aspergillosis NCT01176071 | University Hospital, Gasthuisberg | — |
| Terminated | Validation of an Index of Neutropenia (D-index) in Febrile Neutropenic Cancer Patients NCT00982540 | Universidade Federal do Rio de Janeiro | N/A |
| Terminated | A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And O NCT00836875 | Pfizer | Phase 3 |
| Completed | Invasives Aspergillosis in Acute Myeloid Leukemia NCT02900430 | University Hospital, Brest | — |
| Completed | Influence of Drug-drug Interactions on the Pharmacokinetics (PK) of Voriconazole NCT01080651 | Seoul National University Hospital | Phase 1 |
| Completed | Diagnostic and Management Strategies for Invasive Aspergillosis NCT00816088 | King's College Hospital NHS Trust | — |
| Completed | Diagnosing Pulmonary Aspergillosis in Patients With Hematological Malignancies: A Multicentre Prospective Eval NCT01430663 | Heidelberg University | — |
| Unknown | Surveillance for Nosocomial Infections in Pediatric Cancer Patients NCT00843804 | University Hospital, Bonn | — |
| Completed | Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis NCT00404092 | University of Cologne | Phase 2 |
| Completed | Galactomannan Antigen in Bronchoalveolar Lavage in the Diagnosis of Invasive Aspergillosis in Neutropenic Pati NCT01128907 | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | — |
| Terminated | Micafungin Salvage Mono-therapy in Invasive Aspergillosis NCT00376337 | Astellas Pharma Inc | Phase 2 |
| Completed | A Multicentre Randomised Controlled Trial Comparing Two Strategies for the Diagnosis of Invasive Aspergillosis NCT00163722 | Bayside Health | Phase 3 |
| Completed | COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of Invasive Aspergillosis NCT00334412 | Gilead Sciences | Phase 4 |
| Completed | Study Safety/Efficacy of AmBisome Loading Dose Regimen Versus Standard AmBisome Regimen for Initial Treatment NCT00158730 | Gilead Sciences | Phase 3 |
| Unknown | Invasive Aspergillosis After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) NCT00838643 | Ospedale Santa Croce-Carle Cuneo | — |
| Completed | Diagnosing Invasive Aspergillosis by Polymerase Chain Reaction (PCR) Based Investigation of Bronchoalveolar La NCT01448226 | Heidelberg University | — |